Last Posted: Aug 26, 2021
- Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1,607 patients.
Loscocco Giuseppe G, et al. American journal of hematology 2021 8
- Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
Zulkeflee Razan Hayati, et al. International journal of environmental research and public health 2021 7 (14)
- Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat Naseema, et al. American journal of hematology 2021 4 (7) 781-789
- Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs.
El-Ghonemy Mohammed Sabry, et al. Asian Pacific journal of cancer prevention : APJCP 2021 4 (4) 1195-1201
- Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era.
Lee Jong-Mi, et al. Journal of clinical medicine 2021 3 (5)
- Myeloproliferative neoplasms and clonal hematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.
Papo Matthias, et al. Rheumatology (Oxford, England) 2021 4
- Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms.
Schino Mattia, et al. Haematologica 2020 0
- The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
Pérez Encinas Manuel M, et al. European journal of haematology 2020 12
- Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat.
Oppliger Leibundgut Elisabeth, et al. Haematologica 2020 7
- Thrombophilic Risk of Factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin Mutations in Essential Thrombocythemia Egyptian Patients.
El-Ghonemy Mohamed S, et al. Advances in hematology 2020 0 7695129
- The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
Byun Ja Min, et al. Anticancer research 2019 11 (11) 6273-6282
- Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms.
Porto-Soares Moysés Antonio, et al. Hematology, transfusion and cell therapy 2019 10
- Gene Polymorphism of Xenobiotic Biotransformation Enzymes in Patients with Classical Ph-Negative Myeloproliferative Neoplasms.
Ovsepyan V A, et al. Bulletin of experimental biology and medicine 2019 11
- Mutational profiling in myelofibrosis: implications for management.
Bose Prithviraj et al. International journal of hematology 2019 Oct
- TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
Matsuguma Masafumi, et al. International journal of hematology 2019 9
- Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu Hoang Anh, et al. Asian Pacific journal of cancer prevention : APJCP 2019 0 (9) 2775-2780
- Family Members at Higher Risk for Blood Cancers
P Harrison, Medscape, September 9, 2019
- Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu Prajwal, et al. Annals of hematology 2018 1 (1) 109-121
- Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis.
Li Bing, et al. Journal of hematology & oncology 2017 0 (1) 99
- Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia.
Ji Liying, et al. Experimental and therapeutic medicine 2017 3 (3) 947-951
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.